Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Launched in 2018, the Morningstar Minority Empowerment Index highlights companies that demonstrate a strong commitment to ...
Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...
Seeking Alpha on MSN4h
Biogen, Eisai Alzheimer’s drug review delayed in EUBiogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback